Skip to content

    Sakar Healthcare Limited

    SAKAR
    Healthcare·11 Feb 2026
    Management Summary

    Sakar Healthcare reported a strong Q3 FY26, with revenue growing 62% YoY to INR 7,034 lakhs and PAT surging 126% YoY to INR 1,025 lakhs, primarily driven by its oncology vertical. The company's EU GMP-approved oncology facility is now a manufacturing source for the EU, with 11 marketing authorizations secured and 10 molecules in various stages of technical transfer. Management expects this momentum to continue, projecting 60-70% YoY growth for oncology in FY27, while maintaining a controlled capex and stable tax rate due to MAT credit.

    Highlights

    5

    • Revenue from operations for Q3 FY26 increased by 62% YoY to INR 7,034 lakhs, demonstrating robust growth.

    • Profit After Tax (PAT) for Q3 FY26 surged by 126% YoY to INR 1,025 lakhs, driven by operating leverage and better product mix.

    • The EU GMP approved oncology facility at Bavla has gained significant strategic relevance, with 11 marketing authorizations already received across Europe and emerging markets.

    • The company has 10 molecules in the tech transfer process, with Imatinib and another product already approved, and 2 more expected within two months, indicating a strong pipeline.

    • Management projects a 60-70% year-on-year growth for the oncology business in FY27, targeting an EBITDA margin of around 30% for the segment.

    Concerns

    2

    • There was a discrepancy in the reported breakdown of 9M oncology sales, where the sum of exports (INR 30.81 crores) and domestic sales (INR 8.62 crores) did not match the stated total oncology turnover (INR 69.45 crores).

    • Conflicting statements were made regarding employee costs, with an analyst noting an increase from INR 8.3 crores to INR 9.9 crores, while management stated Q3 costs were around INR 8 crores and then mentioned INR 9.5 crores for Q3/Q4, indicating some lack of clarity.

    What Changed1

    vs Q4 FY26

    Guidance items15 → 6 (-9)
    Key financials

    Metrics

    8

    Periods

    2

    Headline

    5
    • Revenue from Operations
      7,034 lakhs
      YoY+62%
    • EBITDA
      1,859 lakhs
      YoY+58.0%
    • EBITDA Margin
      26%
    • PAT
      1,025 lakhs
      YoY+126%
    • Gross Margins
      49%

    9M

    3
    • Revenue
      18,064 lakhs
      YoY+42%
    • EBITDA
      4,265 lakhs
      YoY+26%
    • PAT
      1,946 lakhs
      YoY+66%

    Segment breakdown

    • Oncology (Q3 FY26)₹31 Cr30.9%
    • Oncology (9M FY26)₹69.45 Cr69.1%
    Donut· Share of Total Turnover

    Capital allocation

    1
    high confidence
    CategoryHeadline
    Capex

    ₹9 crores

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    FY26 Revenue Growth
    40%+
    		High
    Revenue
    Oncology Revenue Growth
    60-70%
    		High
    Profitability
    Oncology EBITDA Margin
    30%
    		Medium
    Tax Rate
    Effective Tax Rate
    18-19%
    		High
    Tax Rate
    Effective Tax Rate
    25-26%
    		High
    Product Pipeline
    Tech Transfer Products Commercialization
    All 10 products
    		Medium

    What to watch in Q4 FY26

    4

    Commercialization of EU-approved products (first dispatches)

    Q1 FY27
    CurrentOrders received, manufacturing scheduled, dispatch in May or April 2026.
    TargetActual dispatch and revenue recognition from initial EU supplies.

    Why it matters

    Verifies the start of commercialization for key EU market entries, which is a major milestone for the company's global expansion strategy.

    So we have already received the orders, POs, and currently the manufacturing has been scheduled. And we'll be maybe dispatching either in May or maybe in April, depending upon the whether the setup is ready for us.

    Risks & concerns

    1
    RiskSeverity

    Regulatory approvals and timelines for new products

    The company has 100+ MA submissions and 200 dossiers with partners, but the timing of approvals and 'getting a slot' for MA in Europe can be a challenge, as certain things are not in management's hand. — Management acknowledged

    medium

    Q&A highlights

    8

    “So the Q3 turnover for the oncology business in all was INR31 crores, out of which INR19 crores was exports and majority is of it was towards the EU. And the domestic was around INR12 crores. And if I say for the nine months, for the nine months the turnover for the oncology business has been INR69 crores – INR69.45 crores, of which INR30.81 crores is exports and rest INR8.62 crores is the domestic sales.”

    Provides specific segment revenue breakdown for the oncology business, highlighting export vs. domestic contribution.

    asked by Ankit Gupta

    2 min read5 chapters

    Detailed Narrative

    01

    Robust Financial Performance Driven by Oncology

    Sakar Healthcare delivered strong financial results for Q3 FY26, with revenue from operations growing 62% year-on-year to INR 7,034 lakhs. Profit After Tax (PAT) saw an even more significant increase of 126% year-on-year, reaching INR 1,025 lakhs. This performance was largely attributed to the oncology vertical, which contributed INR 31 crores in Q3. For the nine months ended December 31, 2025, revenue stood at INR 18,064 lakhs, a 42% YoY increase, with PAT growing 66% to INR 1,946 lakhs.

    02

    Strategic Expansion in European Oncology Market

    The company's EU GMP-approved oncology facility at Bavla is now a key manufacturing source for the EU, enhancing its global strategic relevance. Sakar Healthcare has already secured 11 marketing authorizations across Europe and emerging markets, with 10 molecules currently undergoing technical transfer. Management highlighted Imatinib as a significant product with a European market opportunity of $200-$250 million, expecting commercialization of these tech-transferred products to commence from Q1 FY27.

    03

    Strong Product Pipeline and Dossier Progress

    Sakar Healthcare continues to advance its product pipeline, with 211 oncology dossiers shared globally and 102 already submitted across partner markets. Out of 32 developed oncology dossiers, 21 have been submitted, and 11 have received marketing authorizations. The R&D teams are focused on developing non-infringing patent formulations and differentiated oncology products, which are expected to bolster future revenue streams and support high-margin growth.

    04

    Optimistic Growth Outlook and Margin Targets

    Management expressed high confidence in sustaining growth, projecting a 40%+ year-on-year revenue growth for FY26. Specifically for the oncology segment, a robust 60-70% year-on-year growth is anticipated for FY27. The company aims to achieve an EBITDA margin of approximately 30% for its oncology business, up from the current 26% reported in Q3 FY26, driven by improved efficiency and product mix.

    05

    Controlled Capital Expenditure and Stable Tax Rates

    Capital expenditure for the nine months of FY26 totaled INR 39 crores, with INR 9 crores spent in Q3 on plant and machinery upgrades. The company stated that major capex plans are now complete, and no significant capex is foreseen for FY27, with maintenance capex expected to be around INR 65 lakhs per quarter. The current lower tax rate of 18-19% for FY26 and FY27 is attributed to MAT credit utilization, with a return to normal tax slabs of 25-26% expected post-FY27.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.